TAIPEIBIO CO., LTD.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
1. NeoGraft
2. NeoGraft C
3. NeoGraft E
2. NeoGraft C
3. NeoGraft E
The content above was translated by Ai
Founded Year
2014
Unified Business No.
24552024
Status
Active
Number of Employees
0
Total Paid-in
Capital
83,000,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Taipeibio is a pioneer of regenerative-collagen driven tissue regeneration technology, and can repair various bone defects in bone, joint, ligament and cartilage. We are involved with some of the top notch medical materials in tissue regeneration. Taipeibio has decades of experience in gene regulation/ Nano DMX® (Duo Matrix) technologies and for 15 years has had convincing top stress-bearing data proving safety and efficacy. This includes more than 50 high-impact papers published and 20 patents approved in the U.S.. (IP firms: Fish & Richardson / Cesari & McKenna Boston)
In 2015, we built a GMP-compliance facility in Boston area (New England Osteogenesis Inc.. -NEO) supported by our research arms with the followings,
- successfully transferred our R&D platform and manufacturing process from our Taiwan government-funding lab to U.S. for GMP mass production in 2018.
- a comprehensive quality control of source materials and optimized manufacturing process and know-how to minimize the cost and to accelerate the process for FDA fast-track clearance.
Taipeibio founder Dr. Thomas Wen-Fu Lai has contributed to tissue engineering and molecular imaging technologies for over 30 years and is a pioneer researcher in the field of tissue regeneration (SG/MG Lab-Harvard, IY Lab-MIT 1989) and bone/cartilage molecular imaging (RW Lab-MGH 2000).
In 2015, we built a GMP-compliance facility in Boston area (New England Osteogenesis Inc.. -NEO) supported by our research arms with the followings,
- successfully transferred our R&D platform and manufacturing process from our Taiwan government-funding lab to U.S. for GMP mass production in 2018.
- a comprehensive quality control of source materials and optimized manufacturing process and know-how to minimize the cost and to accelerate the process for FDA fast-track clearance.
Taipeibio founder Dr. Thomas Wen-Fu Lai has contributed to tissue engineering and molecular imaging technologies for over 30 years and is a pioneer researcher in the field of tissue regeneration (SG/MG Lab-Harvard, IY Lab-MIT 1989) and bone/cartilage molecular imaging (RW Lab-MGH 2000).
The content above was translated by Ai
